J&J secures extended NICE approval for Darzalex following earlier refusal - Pharmaceutical Technology

NICE has preliminarily recommended Darxalex-containing D-VRd for NHS use as a first-line treatment for transplant-ineligible multiple myeloma. NICE has preliminarily recommended D-VRd for NHS use as a first-line treatment for transplant-ineligible multiple myeloma. NICE has issued a final draft guidance recommending Darzelx-containing multiple myeloma regimen, D-VRd for use in the NHS in untreated, transplant-ineligible patients. Credit: Nemes Laszlo / Shutterstock.com. Johnson & Johnson’s (J&J’s) blockbuster cancer therapy, Darzalex (daratumumab), is set to secure a wider recommendation from the UK’s health watchdog in multiple myeloma, marking a change of heart from the agency, while expanding the drug’s role in treatment across…

Source: Pharmaceutical Technology